

Statistical Analysis Plan

TRIAL FULL TITLE	Multi-Drug Combination-Therapies to Prevent the Development of Drug Resistance <i>Phase II Controlled Clinical Trial Assessing Candidate Regimens of Multiple-Antimalarial Combinations for the Treatment of Uncomplicated Malaria in Africa</i>
SAP VERSION	MultiMal_SAP03032020
SAP VERSION DATE	03/MAR/2020
TRIAL STATISTICIANS	Johannes Mischlinger and Sebastian Wicha
PRINCIPAL INVESTIGATOR	Michael Ramharter
SAP AUTHORS	Johannes Mischlinger and Sebastian Wicha

1 Addendum related to Analysis Populations (Changes in Yellow)

1.1.1 Full Analysis Population

- All subjects who received any study drug

1.1.2 Per Protocol Population

All participants who received a full 3-day course of study drugs

AND

All participants having successfully completed sufficient study visits to calculate:

- PCR corrected adequate clinical and parasitological response on Day 42

OR

- PCR corrected cure rate on day 28

1.1.3 Safety Population

- All subjects who received any study treatment (including control) but excluding subjects who drop out prior to receiving any treatment.